EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Subclinical atrial fibrillation: a narrative review of current evidence and treatment strategies

Mohammed Dhuwayhi Ghazi Alotaibi

Bali Medical Journal · 03.08.2026 · 15 (2) · 260-267

DOI: 10.15562/bmj.v15i2.5918 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Bali Medical Journal, online erschienen am 03.08.2026. Verfasst von Mohammed Dhuwayhi Ghazi Alotaibi. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Subclinical atrial fibrillation (SCAF) is being detected more and more often as cardiac implantable electronic devices and wearable monitors become part of routine practice. Unlike clinically overt atrial fibrillation, SCAF is asymptomatic and detected only through device interrogation or prolonged monitoring, without any prior ECG-confirmed diagnosis. Because its stroke risk, underlying mechanisms, and treatment pathways differ meaningfully from those of clinical AF, existing management strategies cannot simply be transferred over, and dedicated guidance remains limited. This study aimed to evaluate the current evidence and treatment strategies of SCAF.

Methods

This narrative review followed SANRA principles and articles taken from PubMed/MEDLINE and Google Scholar searches (through March 2025), supplemented by manual screening of reference lists and major guideline documents, including the 2023 ACC/AHA and 2024 ESC recommendations. Rather than applying strict inclusion criteria, the review prioritized randomized trials, guideline-defining subgroup analyses, and large observational studies, with findings synthesized thematically across definitions, screening approaches, risk stratification, and treatment.

Results

SCAF carries a genuine but uneven stroke risk that depends heavily on episode duration, overall arrhythmia burden, and background patient risk. A puzzling disconnect between arrhythmia episodes and actual stroke timing suggests SCAF may reflect an underlying atrial cardiomyopathy rather than acting purely as a direct trigger. The two major anticoagulation trials, NOAH-AFNET 6 and ARTESiA, produced results that appeared inconsistent at first but align once trial design differences are accounted for, and pooled analysis shows a consistent, though modest, benefit that comes paired with increased bleeding risk. Detection technology continues to advance, but better detection has not reliably translated into better outcomes.

Conclusion

No uniform treatment pathway currently exists for SCAF. Both major society guidelines still offer only cautious, conditional recommendations, meaning that decisions about anticoagulation should remain individualized, weighing stroke risk against bleeding risk until stronger evidence becomes available.

Zitieren

APA

Alotaibi, M. D. G. (2026). Subclinical atrial fibrillation: a narrative review of current evidence and treatment strategies. Bali Medical Journal, 15(2), 260-267. https://doi.org/10.15562/bmj.v15i2.5918

Vancouver

Alotaibi MDG. Subclinical atrial fibrillation: a narrative review of current evidence and treatment strategies. Bali Medical Journal. 2026;15(2):260-267. doi:10.15562/bmj.v15i2.5918

BibTeX
@article{Alotaibi2026,
  author = {Alotaibi, Mohammed Dhuwayhi Ghazi},
  title = {Subclinical atrial fibrillation: a narrative review of current evidence and treatment strategies},
  journal = {Bali Medical Journal},
  year = {2026},
  volume = {15},
  number = {2},
  pages = {260--267},
  doi = {10.15562/bmj.v15i2.5918}
}
Kostenlos starten →